Please enable JavaScript to continue using this application.

Compare $KRYS vs $KYMR | Chartloom

Compare

$KRYS vs $KYMR

Krystal Biotech Inc · Kymera Therapeutics Inc

KRYS

Krystal Biotech Inc

KYMR

Kymera Therapeutics Inc

Compare $KRYS vs $KYMR

Comparing Krystal Biotech Inc and Kymera Therapeutics Inc

KRYSKrystal Biotech Inc

KYMRKymera Therapeutics Inc

KRYSKrystal Biotech Inc

Market cap

$9.78B

P/E (TTM)

42.10x

Forward P/E (NTM)

39.13x

Forward P/S (NTM)

16.80x

Rev growth (TTM)

22.6%

YTD performance

34.3%

52W performance

77.2%

FCF yield

2.6%

KYMRKymera Therapeutics Inc

Market cap

$9.25B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

456.91x

Rev growth (TTM)

134.8%

YTD performance

54.5%

52W performance

99.7%

FCF yield

-2.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KRYS

KYMR

Detailed metrics comparison

KRYS

Krystal Biotech Inc

KYMR

Kymera Therapeutics Inc

Market Cap

KRYS$9.78B

KYMR$9.25B

Enterprise Value

KRYS$9.35B

KYMR$9.12B

Price

KRYS$331.61

KYMR$112.40

P/E Ratio

KRYS42.10x

KYMRN/A

P/S Ratio

KRYS22.19x

KYMR88.06x

EV/Sales

KRYS21.22x

KYMR86.90x

EV/EBITDA

KRYS42.60x

KYMR0.00x

P/B Ratio

KRYS7.02x

KYMR5.92x

P/FCF Ratio

KRYS37.92x

KYMRN/A

EV/FCF

KRYS36.26x

KYMR-38.34x

PEG Ratio

KRYS1.01x

KYMRN/A

Forward P/E (NTM)

KRYS39.13x

KYMRN/A

Forward P/S (NTM)

KRYS16.80x

KYMR456.91x

Revenue (TTM)

KRYS$440M

KYMR$105M

Revenue Growth (YoY)

KRYS22.6%

KYMR134.8%

Forward Rev Growth

KRYS27.8%

KYMR-62.1%

Gross Margin (TTM)

KRYS94.6%

KYMR0.0%

Operating Margin (TTM)

KRYS44.9%

KYMR0.0%

EBITDA Margin (TTM)

KRYS46.2%

KYMR-322.0%

Net Margin (TTM)

KRYS54.8%

KYMR-285.3%

FCF Margin (TTM)

KRYS58.5%

KYMR-226.6%

Net Income (TTM)

KRYS$241M

KYMR$-300M

FCF (TTM)

KRYS$258M

KYMR$-238M

EPS (TTM)

KRYS$7.88

KYMR-$3.05

ROE (TTM)

KRYS19.3%

KYMR-2150.0%

ROA (TTM)

KRYS17.6%

KYMR-1946.0%

ROIC (TTM)

KRYS19.3%

KYMR-2145.0%

Cash

KRYS$428M

KYMR$124M

Debt

KRYS$0

KYMR$2M

Net Cash/Debt

KRYS$428M

KYMR$122M

Current Ratio (TTM)

KRYS8.32x

KYMR10.34x

Quick Ratio (TTM)

KRYS7.73x

KYMR9.97x

Debt/Equity (TTM)

KRYS0.00x

KYMR0.00x

Debt/Assets (TTM)

KRYS0.0%

KYMR0.0%

Interest Coverage (TTM)

KRYSN/A

KYMRN/A

Net Debt/EBITDA (TTM)

KRYS0.00x

KYMR0.00x

Beta

KRYS0.65

KYMR2.05

52W Performance

KRYS77.2%

KYMR99.7%

YTD Performance

KRYS34.3%

KYMR54.5%

% from 52W High

KRYS-13.3%

KYMR-13.6%

% from 52W Low

KRYS85.1%

KYMR103.4%

Asset Turnover (TTM)

KRYS0.32x

KYMR0.07x

FCF Yield (TTM)

KRYS2.6%

KYMR-2.6%

Earnings Yield (TTM)

KRYS2.5%

KYMR-3.2%

Dividend Yield (TTM)

KRYSN/A

KYMRN/A

Rule of 40

KRYS81.1

KYMR-91.8

EV/GP/RG

KRYS0.65

KYMRN/A

Ticker research

View KRYS research View KYMR research

Metric	KRYS Krystal Biotech Inc	KYMR Kymera Therapeutics Inc
Market & Valuation
Market Cap	$9.78B	$9.25B
Enterprise Value	$9.35B	$9.12B
Price	$331.61	$112.40
P/E Ratio	42.10x	N/A
P/S Ratio	22.19x	88.06x
EV/Sales	21.22x	86.90x
EV/EBITDA	42.60x	0.00x
P/B Ratio	7.02x	5.92x
P/FCF Ratio	37.92x	N/A
EV/FCF	36.26x	-38.34x
PEG Ratio	1.01x	N/A
Forward P/E (NTM)	39.13x	N/A
Forward P/S (NTM)	16.80x	456.91x
Revenue & Growth
Revenue (TTM)	$440M	$105M
Revenue Growth (YoY)	22.6%	134.8%
Forward Rev Growth	27.8%	-62.1%
Profitability
Gross Margin (TTM)	94.6%	0.0%
Operating Margin (TTM)	44.9%	0.0%
EBITDA Margin (TTM)	46.2%	-322.0%
Net Margin (TTM)	54.8%	-285.3%
FCF Margin (TTM)	58.5%	-226.6%
Net Income (TTM)	$241M	$-300M
FCF (TTM)	$258M	$-238M
EPS (TTM)	$7.88	-$3.05
ROE (TTM)	19.3%	-2150.0%
ROA (TTM)	17.6%	-1946.0%
ROIC (TTM)	19.3%	-2145.0%
Financial Health
Cash	$428M	$124M
Debt	$0	$2M
Net Cash/Debt	$428M	$122M
Current Ratio (TTM)	8.32x	10.34x
Quick Ratio (TTM)	7.73x	9.97x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.65	2.05
52W Performance	77.2%	99.7%
YTD Performance	34.3%	54.5%
% from 52W High	-13.3%	-13.6%
% from 52W Low	85.1%	103.4%
Efficiency & Yields
Asset Turnover (TTM)	0.32x	0.07x
FCF Yield (TTM)	2.6%	-2.6%
Earnings Yield (TTM)	2.5%	-3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	81.1	-91.8
EV/GP/RG	0.65	N/A
Ticker research	View KRYS research	View KYMR research

Valuation

P/E Ratio

KRYS

42.10x

P/S Ratio

KRYS

22.19x

KYMR

88.06x

EV/FCF

KYMR

-38.34x

KRYS

36.26x

Growth & revenue

Revenue Growth TTM

KYMR

134.8%

KRYS

22.6%

Forward Revenue Growth

KRYS

27.8%

KYMR

-62.1%

Profitability & performance

Gross Margin

KRYS

94.6%

KYMR

0.0%

ROE

KRYS

19.3%

KYMR

-2150.0%

FCF Yield %

KRYS

2.6%

KYMR

-2.6%

52-Week Performance

KYMR

99.7%

KRYS

77.2%

Detailed metrics comparison

KRYS

Krystal Biotech Inc

KYMR

Kymera Therapeutics Inc

Market Cap

KRYS$9.78B

KYMR$9.25B

Enterprise Value

KRYS$9.35B

KYMR$9.12B

Price

KRYS$331.61

KYMR$112.40

P/E Ratio

KRYS42.10x

KYMRN/A

P/S Ratio

KRYS22.19x

KYMR88.06x

EV/Sales

KRYS21.22x

KYMR86.90x

EV/EBITDA

KRYS42.60x

KYMR0.00x

P/B Ratio

KRYS7.02x

KYMR5.92x

P/FCF Ratio

KRYS37.92x

KYMRN/A

EV/FCF

KRYS36.26x

KYMR-38.34x

PEG Ratio

KRYS1.01x

KYMRN/A

Forward P/E (NTM)

KRYS39.13x

KYMRN/A

Forward P/S (NTM)

KRYS16.80x

KYMR456.91x

Revenue (TTM)

KRYS$440M

KYMR$105M

Revenue Growth (YoY)

KRYS22.6%

KYMR134.8%

Forward Rev Growth

KRYS27.8%

KYMR-62.1%

Gross Margin (TTM)

KRYS94.6%

KYMR0.0%

Operating Margin (TTM)

KRYS44.9%

KYMR0.0%

EBITDA Margin (TTM)

KRYS46.2%

KYMR-322.0%

Net Margin (TTM)

KRYS54.8%

KYMR-285.3%

FCF Margin (TTM)

KRYS58.5%

KYMR-226.6%

Net Income (TTM)

KRYS$241M

KYMR$-300M

FCF (TTM)

KRYS$258M

KYMR$-238M

EPS (TTM)

KRYS$7.88

KYMR-$3.05

ROE (TTM)

KRYS19.3%

KYMR-2150.0%

ROA (TTM)

KRYS17.6%

KYMR-1946.0%

ROIC (TTM)

KRYS19.3%

KYMR-2145.0%

Cash

KRYS$428M

KYMR$124M

Debt

KRYS$0

KYMR$2M

Net Cash/Debt

KRYS$428M

KYMR$122M

Current Ratio (TTM)

KRYS8.32x

KYMR10.34x

Quick Ratio (TTM)

KRYS7.73x

KYMR9.97x

Debt/Equity (TTM)

KRYS0.00x

KYMR0.00x

Debt/Assets (TTM)

KRYS0.0%

KYMR0.0%

Interest Coverage (TTM)

KRYSN/A

KYMRN/A

Net Debt/EBITDA (TTM)

KRYS0.00x

KYMR0.00x

Beta

KRYS0.65

KYMR2.05

52W Performance

KRYS77.2%

KYMR99.7%

YTD Performance

KRYS34.3%

KYMR54.5%

% from 52W High

KRYS-13.3%

KYMR-13.6%

% from 52W Low

KRYS85.1%

KYMR103.4%

Asset Turnover (TTM)

KRYS0.32x

KYMR0.07x

FCF Yield (TTM)

KRYS2.6%

KYMR-2.6%

Earnings Yield (TTM)

KRYS2.5%

KYMR-3.2%

Dividend Yield (TTM)

KRYSN/A

KYMRN/A

Rule of 40

KRYS81.1

KYMR-91.8

EV/GP/RG

KRYS0.65

KYMRN/A

Ticker research

View KRYS research View KYMR research

Metric	KRYS Krystal Biotech Inc	KYMR Kymera Therapeutics Inc
Market & Valuation
Market Cap	$9.78B	$9.25B
Enterprise Value	$9.35B	$9.12B
Price	$331.61	$112.40
P/E Ratio	42.10x	N/A
P/S Ratio	22.19x	88.06x
EV/Sales	21.22x	86.90x
EV/EBITDA	42.60x	0.00x
P/B Ratio	7.02x	5.92x
P/FCF Ratio	37.92x	N/A
EV/FCF	36.26x	-38.34x
PEG Ratio	1.01x	N/A
Forward P/E (NTM)	39.13x	N/A
Forward P/S (NTM)	16.80x	456.91x
Revenue & Growth
Revenue (TTM)	$440M	$105M
Revenue Growth (YoY)	22.6%	134.8%
Forward Rev Growth	27.8%	-62.1%
Profitability
Gross Margin (TTM)	94.6%	0.0%
Operating Margin (TTM)	44.9%	0.0%
EBITDA Margin (TTM)	46.2%	-322.0%
Net Margin (TTM)	54.8%	-285.3%
FCF Margin (TTM)	58.5%	-226.6%
Net Income (TTM)	$241M	$-300M
FCF (TTM)	$258M	$-238M
EPS (TTM)	$7.88	-$3.05
ROE (TTM)	19.3%	-2150.0%
ROA (TTM)	17.6%	-1946.0%
ROIC (TTM)	19.3%	-2145.0%
Financial Health
Cash	$428M	$124M
Debt	$0	$2M
Net Cash/Debt	$428M	$122M
Current Ratio (TTM)	8.32x	10.34x
Quick Ratio (TTM)	7.73x	9.97x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.65	2.05
52W Performance	77.2%	99.7%
YTD Performance	34.3%	54.5%
% from 52W High	-13.3%	-13.6%
% from 52W Low	85.1%	103.4%
Efficiency & Yields
Asset Turnover (TTM)	0.32x	0.07x
FCF Yield (TTM)	2.6%	-2.6%
Earnings Yield (TTM)	2.5%	-3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	81.1	-91.8
EV/GP/RG	0.65	N/A
Ticker research	View KRYS research	View KYMR research